Selective histamine H1 receptor antagonist, no obvious anticholinergic and anti-5-hydroxytryptamine effect, not easy to pass the blood-cerebrospinal fluid barrier, clinical use of central nervous system inhibitory effect is relatively mild

Selective histamine H1 receptor antagonist, no obvious anticholinergic and anti-5-hydroxytryptamine effect, not easy to pass the blood-cerebrospinal fluid barrier, clinical use of central nervous system inhibitory effect is relatively mild

Extract from the above information

This product is a new generation of macrolide antibiotics, mainly acting on Gram-positive bacteria, anaerobic bacteria, chlamydia and mycoplasma. Its in vitro antibacterial effect is similar to that of erythromycin, and its activity against streptococci, Haemophilus ducreyi, Chlamydia trachomatis, Mycoplasma pneumoniae, oral or vaginal anaerobic bacteria is similar to that of erythromycin; its effect on Campylobacter, Bordetella pertussis and Haemophilus influenzae is not as good as that of erythromycin; it also has an inhibitory effect on Mycobacterium tuberculosis, most atypical mycobacteria, Campylobacter jejuni, Corynebacterium diphtheriae, and Pasteurella multocida; it has no antibacterial activity against G bacteria. Some bacteria have cross-resistance to erythromycin and this product, and this product is particularly effective against mycoplasma, chlamydia and Legionella infections. Its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.